Brooke Pillifant

GBT Announces Updated 24-Week Efficacy Data

All Patients Enrolled in Phase 3 HOPE Study Showing Statistically Significant and Sustained Improvements in Hemoglobin with Voxelotor Global Blood Therapeutics, Inc. (GBT) today announced new results from its Phase 3 HOPE Study of voxelotor in patients ages 12 and older with sickle cell disease (SCD). The findings from 274 adolescents and adults treated with

GBT Announces Updated 24-Week Efficacy Data Read More »

SC Community receives Grants from Novartis STEP Program

Five nonprofit organizations to receive up to $250,000 through Novartis STEP Program™ to support sickle cell patient initiatives The Solutions to Empower Patients (STEP) Program™ continues to help nonprofit organizations deliver new solutions to address unmet patient needs This year’s focus is on addressing some of the most pressing issues in the sickle cell disease

SC Community receives Grants from Novartis STEP Program Read More »

Shopping Cart
Scroll to Top